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Background: Severe chronic obstructive pulmonary disease is associated with high HDL choles-
terol (HDL-C). We sought to examine the effect of lung transplantation on lipid profiles in
patients with COPD.
Methods: We analyzed 101 lung transplant recipients in a retrospective cohort of patients from
two centers in whom lipid values were available both before as well as after transplantation.
Sixty-one subjects were transplanted for severe COPD (93% GOLD stage 4).
Results: Eighty-nine percent of subjects with COPD exhibited a decline in HDL-C. Median
decline for the COPD cohort was 25 mg/dL (IQR 12e38 mg/dL, p < 0.0001). Non-COPD subjects
exhibited no significant changes in HDL-C. Other lipid changes in the COPD cohort included
a rise in triglycerides of 70 mg/dL (IQR 35 to 140, p < 0.0001). Decreases in HDL-C levels were
independent from the rise in triglyceride levels. Neither LDL-C nor non-HDL-C demonstrated
significant changes. Subjects with greater increases in prednisone exposure post-transplant ex-
hibited lesser declines in HDL-C. Compared with tacrolimus, cyclosporine had no effect onf Maryland Physicians, Division of Pulmonary and Critical Care Medicine, 110 South Paca Street, 2nd
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1962 R.M. Reed et al.observed changes in HDL-C or triglycerides, but was associated with a greater median rise in
LDL-C.
Conclusions: In patients with COPD, lung transplantation results in reductions in the serum
levels of HDL-C. These changes are not observed in patients undergoing lung transplantation
for diagnoses other than COPD.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality, affecting up to 10% of the
US population.1 It remains the leading indication for lung
transplantation worldwide.2 COPD is associated with an
increased risk of cardiovascular disease (CVD) independent
of the common comorbidities of tobacco exposure, age,
hypertension, diabetes mellitus, or hyperlipidemia.3
Cardiovascular disease remains a leading cause of death
in COPD4,5 and although the major limitation to long term
survival after lung transplantation is graft failure, cardio-
vascular disease results in a significant proportion of the
morbidity and mortality following lung transplantation.2
A number of factors in lung transplant patients may
increase cardiovascular risk. Hyperlipidemia following lung
transplantation occurs in 24.2% of one-year survivors and
56.5% of five-year survivors.2 Previously, mechanisms of
hyperlipidemia in solid organ transplantation have been
attributed primarily to effects of medications used to
suppress rejection.6 Common immunosuppressive regimens
typically result in lipid changes typically consisting of
increases in total cholesterol, LDL-C, and triglycerides with
minimal effects on HDL-C.6
Advanced COPD itself is associated with elevated levels
of HDL-C.7,8 Several theories may explain this phenomenon:
(1) Survival bias may reduce the prevalence of patients with
low HDL-C, who may die from cardiovascular disease prior
to the development of advanced COPD; (2) abnormalities of
HDL metabolism may represent a risk factor for the
development of COPD; (3) COPD pathology may be causal in
elevating HDL-C; or (4) COPD treatment could account for
the elevated HDL-C observed. In this analysis of patients
pre and post lung transplant, we studied changes in serum
lipid profiles and compared subjects with COPD to those
transplanted for other indications. Our hypothesis was that
the previously observed increases in triglycerides and LDL-C
levels would be observed in all subjects, whereas the high
HDL-C levels observed prior to transplantation would
decline with transplantation only in subjects with COPD.Methods
This study was approved by the investigational review
boards of the Johns Hopkins University (NA_00022856) and
the University of Maryland School of Medicine (HP-
00047556). Fasting lipid profiles before and during a period
of clinical stability following lung transplantation were
available in 61 subjects transplanted for COPD and
a comparison cohort of 40 subjects who received lungtransplants for other reasons. Clinical stability was defined
as the absence of hypoxemia or high-dose steroids (greater
than prednisone 60 mg or equivalent). There were no
samples included from an immediate post-operative
period, nor from periods of suspected lower respiratory
tract infections. The following data were recorded:
demographics, anthropometrics, pulmonary function,
medical comorbidities, medications, and lipid profile
values.
Statistical analysis
Continuous data were expressed as median (interquartile
range e IQR). Categorical data were presented as counts
and percentages. Nonparametric tests were favored in the
analysis to avoid type 1 error. Changes in lipid values with
transplantation were assessed using Wilcoxon matched-
pairs signed-rank tests. Comparison of continuous vari-
ables according to diagnosis or calcineurin inhibitor selec-
tion was performed using Wilcoxon rank-sum tests. To
examine variables correlating to change in HDL-C levels
with transplant, univariate analyses were performed using
Pearson’s or Spearman’s correlation. Those variables
correlating with a P value of 0.4 or lower were examined for
inclusion in a multivariate model by using reverse stepwise
multiple linear regression with a threshold for inclusion in
the final model of P < 0.2. Modeling assumptions for linear
regression were confirmed, no collinearity was found, and
residuals were inspected for normal distribution. Analyses
were performed using Stata Statistical Software, Release
11.0 (Stata Corporation; College Station, TX).Results
Clinical characteristics of the 101 study subjects are
described in Table 1 according to diagnosis. Sixty-one
subjects were transplanted for COPD and the remaining 40
were transplanted for other diagnoses. Ninety-three
percent of the subjects with COPD were GOLD stage IV.
Other diagnoses primarily included idiopathic pulmonary
fibrosis in 32 (80%) and sarcoidosis in 5 (12.5%). There were
no patients with cystic fibrosis and only one with isolated
pulmonary arterial hypertension. The two remaining
subjects underwent heart-lung transplantation for heart
failure with concomitant lung disease and severe pulmo-
nary hypertension. Ninety-five percent of subjects received
oxygen therapy for hypoxemia prior to transplantation. The
most common post-transplant medical immunosuppressive
regimen did not differ between groups and included
tacrolimus, mycophenolate mofetil, and prednisone. There
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smoking either before or after transplantation.
Lipid changes with transplantation are summarized in
Table 2 and Fig. 1. Eighty-nine percent of the subjects
transplanted for COPD experienced a decline in HDL-C
levels following transplantation. The median decline was
25 mg/dL (IQR 12e38 mg/dL, p < 0.0001). Pre-transplant
HDL-C levels were 69 mg/dL (IQR 51e78) for men and
79 mg/dL (IQR 66e93) for women and fell to 46 mg/dL (IQR
34e57) for men and 54 mg/dL (IQR 41e58) for women.
While pre-transplant HDL-C levels were significantly
different between men and women (PZ 0.005), the HDL-C
difference by gender was no longer significant after trans-
plant (P Z 0.13) due to a trend toward greater declines in
HDL-C levels occurring with transplant in women. Other
lipid changes in the COPD group included a rise in median
triglyceride levels of 70 mg/dL (IQR 35e140 mg/dL,
p < 0.0001). The degree of rise in triglycerides did not
correlate with the degree of fall in HDL-C (PZ 0.8, Fig. 2).
The only significant change observed in the non-COPD
cohort was a median rise in triglycerides of 33 mg/dL (IQR
0 to 89, p Z 0.01). Lipid studies were performed a median
of 212 days (IQR 116e460) before transplant in the COPD
group versus 166 days (IQR 91e291) in the comparison
cohort (p Z 0.08). Post-transplant lipid studies were per-
formed a median of 268 days (IQR 115e457) in the COPD
cohort versus 244 (IQR 82e615) in the comparison cohort
(p Z 1.0). After controlling for changes in BMI and pred-
nisone dose, there was no significant correlation between
timing of lipid evaluation in relation to transplantation and
the changes in HDL-C observed. No differences in lipid
profiles associated with statin use were found before or
after transplantation, nor did the addition of statin therapy
at the time of transplantation correlate to significant
differences. Twenty six percent of patients in the COPDTable 1 Cohort characteristics.
COPD (n Z 61)
Demographics
Age at transplant (yrs) 60 (54e63)
Male Gender (%) 27 (44%)
Caucasian Race (%) 54 (89%)
BMI 25 (23e28)
Diabetes Mellitus 10 (16%)
Tobacco exposure (pk-yrs) 52 (35e70)
Pulmonary Function
FVC% 47 (38e55)
FEV1% 18 (15e23)
FEV1/FVC% 30 (26e36)
TLC % 109 (97e123)
RV% 209 (160e254)
DLCO% 28 (22e42)
Medications
Statin 20 (33%)
Inhaled Beta Agonist 59 (97%)
Prednisone use (%) 31 (51%)
Prednisone Dose (mg/day) 1.25 (0e10)
BMI, body mass index; FVC, forced vital capacity; FEV1, forced expira
DLCO, diffusing capacity for carbon monoxide. Data are expressed as
tained through Wilcoxon rank-sum, Chi-square, or Fisher’s exact testgroup and 35% of the patients in the non-COPD group had
statin therapy added between the pre- and post-transplant
observations. No patient took niacin either before or after
transplantation. With transplant, the non-COPD cohort
compared to the COPD cohort exhibited a greater decline in
BMI 2.2 (IQR 0.9 to 5) vs. 0.4 (IQR 2.2 to 2.6,
pZ 0.0007, but post-transplant diabetes mellitus was more
prevalent 70% vs. 42%, p Z 0.005. There was a non-
significant (p Z 0.07) greater reduction in prednisone
dose occurring with transplant in the non-COPD cohort
compared to the COPD cohort.
All patients were treated with calcineurin inhibitors
after transplantation; no patient received sirolimus. The
effect of calcineurin inhibitor selection on lipid changes
with transplant did not differ significantly between the
entire cohort and the COPD-only cohort (data not shown).
Data are presented for the COPD cohort (Table 3) as
changes in this group was the primary focus of this study.
Seventy-five percent of subjects took tacrolimus, the
remainder took cyclosporine. Tacrolimus and cyclosporine
groups were matched with no significant differences in
distribution of gender (pZ 0.3), change in prednisone dose
with transplant (p Z 0.9), change in BMI (p Z 0.9), or the
addition of statin therapy at the time of transplant
(p Z 1.0). Cyclosporine was associated with significant
increases in LDL-C levels compared to tacrolimus, whereas
selection of calcineurin agent did not affect the observed
HDL-C changes (Table 3).
In univariate analysis of HDL-C changes (Table 4) in COPD
subjects, only changes in prednisone dose was significantly
associated with differences in HDL-C change with trans-
plant. Only gender and change in prednisone doses were
found to contribute to a multivariate model by the selec-
tion methods outlined above, and in this model only change
in prednisone retained significant correlation with changesNon-COPD (n Z 40) Between group
61 (52e67) 0.48
25 (63%) 0.07
28 (70%) 0.03
30 (26e33) 0.0001
15 (38%) 0.016
15 (0e35) <0.0001
43 (34e61) 0.58
46 (37e63) <0.0001
83 (75e88) <0.0001
46 (37e53) <0.0001
49 (40e65) <0.0001
27 (21e37) 0.50
18 (45%) 0.22
12 (30%) <0.0001
28 (70%) 0.056
10 (0e17.5) 0.002
tory volume in 1 s; TLC, total lung capacity; RV, residual volume;
medians (IQR) or as counts and percentages. P values were ob-
s as appropriate.
Table 2 Lipid changes with transplant.
Within group comparison of lipid changes
Within group COPD (n Z 61) Non-COPD (n Z 40)
Pre Post P Pre Post P
Total cholesterol (mg/dL) 207 (177e242) 199 (161e230) 0.22 182 (152e208) 171 (142e213) 0.51
Triglycerides (mg/dL) 92 (63e111) 149 (110e237) <0.0001 134 (94e182) 166 (118e241) 0.002
LDL-C (mg/dL) 112 (85e139) 100 (81e130) 0.30 106 (80e126) 87 (67e115) 0.35
HDL-C (mg/dL) 74 (62e88) 50 (40e58) <0.0001 44 (37e56) 42 (35e53) 0.46
Non-HDL Cholesterol (mg/dL) 126 (100e158) 139 (114e181) 0.18 138 (100e158) 122 (100e163) 0.57
LDL-C/HDL-C ratio 1.44 (1.11e1.90) 2.02 (1.48e3.04) 0.0001 2.54 (1.56e3.00) 1.97 (1.33e2.93) 0.32
TC/HDL-C ratio 2.69 (2.29e3.14) 3.98 (2.90e5.03) <0.0001 4.18 (2.95e4.89) 3.76 (3.27e5.04) 0.89
Between group comparisons of lipid changes
COPD (n Z 61) Non-COPD (n Z 40) P
ΔTotal cholesterol (mg/dL) 11 (49 to 37) 12.5 (52 to 38) 0.79
ΔTriglycerides (mg/dL) 70 (35e140) 33 (1e89) 0.008
ΔLDL-C (mg/dL) 5.5 (48.5 to 23.5) 7 (47 to 28.5) 1.0
ΔHDL-C (mg/dL) 25 (38 to 12) 3 (11.5 to 8) <0.0001
ΔNon-HDL Cholesterol (mg/dL) 5.4 (27e55) 10 (45 to 32) 0.17
ΔLDL-C/HDL-C ratio 0.53 (0.01e1.24) 0.09 (1.0 to 0.60) 0.0007
ΔTC/HDL-C ratio 0.95 (0.27e2.02) 0.002 (0.90 to 0.75) <0.0001
TC, total cholesterol; Δ signifies post-transplant value subtracted from pre-transplant values; Data are expressed as median (IQR);
1 mmol/L Z 38.665 mg/dL.
1964 R.M. Reed et al.in HDL-C occurring with transplantation (Table 4, Fig. 3). In
the multivariable model, an increase of 10 mg/day of
prednisone between pre- and post-transplant lipid evalua-
tions was associated with an 8.3 mg/dL reduction in the
observed decline in HDL-C (95% CI 1.8e14.8, p Z 0.013)
(Fig. 3).Discussion
Few previous data describe the lipid profile changes asso-
ciated with lung transplantation for COPD. In this study,
patients with COPD exhibited elevated pre-transplant HDL-
C levels that were reduced to levels similar to reference
values after lung transplantation. As LDL-C levels generally
remained unchanged, the LDL/HDL ratio rose significantly.
Prior studies assessing changes in the lipid profile asso-
ciated with solid organ transplantation have consistently
demonstrated a rise in total cholesterol, LDL-C, and
triglycerides, but have not shown reductions in HDL-C.9e13
In contrast to prior observations, our cohort showed no
significant change in LDL-C levels with transplant. This
difference may be explained by two factors: (1) the addi-
tion of statin therapy at transplant in 26% of patients, which
has become common practice due to potential benefits on
allograft function and survival,14 and (2) the lesser effect
tacrolimus exerts on LDL-C levels compared to cyclo-
sporine. Whereas 75% of our subjects received tacrolimus,
previous studies included patients treated exclusively or
predominantly with cyclosporine. In those studies as well as
ours, cyclosporine use was associated with significantly
higher levels of LDL-C compared to tacrolimus.12,13
When changes in HDL-C have been observed to occur
with solid organ transplantation, they have consisted of
increased values. Two studies including a total of 141cardiac transplant recipients observed mean increases of 10
and 13 mg/dL in HDL-C with transplant.9,11 Similar eleva-
tions in HDL-C were observed in liver12 and renal10 trans-
plantation. A recent study of 108 patients undergoing lung
transplantation for cystic fibrosis showed no change in HDL-
C levels with transplantation.13 Similar results in our non-
COPD cohort make less likely the possibility that the find-
ings in our COPD cohort were attributable to study design.
These findings suggest that the fall in HDL-C levels observed
in the COPD cohort cannot be explained solely by transplant
medications or another common aspect of transplantation,
but rather reflect a characteristic unique to COPD. This
supports the possibility of a factor produced in the diseased
lung which results in increased HDL-C levels (see below).
Furthermore, the decline does not support the assertion
that the observation of high HDL-C levels in advanced COPD
is a result of survival bias as a significant change with
transplantation would be unexpected if this were the
primary contributor. Nor would changes in BMI or diabetes
prevalence be expected to preferentially affect patients
with COPD. While pre-transplant BMI was inversely related
to HDL-C levels, changes in BMI with transplantation bore
no significant correlation to the changes in HDL-C levels
observed. The development of the metabolic syndrome
associated with diabetes mellitus appears unrelated as
neither diabetes, nor changes in triglycerides, correlated to
the decline in HDL-C.
The effect of prednisone in this study was somewhat
counter-intuitive. Chronic prednisone frequently worsens
glycemic tolerance and promotes a diabetic profile of
reduced HDL-C, whereas we observed the opposite effect
on HDL-C. Pre-transplant prednisone exposure was associ-
ated with higher levels of HDL-C and a greater degree of
decline in HDL-C following transplantation to levels nearly
identical to those of non-exposed pre-transplant subjects.
Fig. 1 Lipid changes occurring with lung transplantation in 61 COPD patients.
Fig. 2 Correlation between changes in HDL-C and triglycer-
ides with transplant in COPD cohort.
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can result in increased levels of HDL-C,15e17possibly by
reducing cholesteryl ester transfer protein (CETP) activity18
and stimulating hepatic production of apoAI (the principle
protein of HDL).19 Pre-transplant prednisone exposure
cannot explain the decline in HDL-C, however, as a similar
decline in HDL-C levels was observed in subjects without
pre-transplant prednisone exposure in whom prednisone
was added post-transplant. Furthermore, the non-COPD
cohort exhibited a non-significant (p Z 0.07) greater
reduction in prednisone dose with transplant. This would
have been expected to result in a decline in HDL-C, but
these changes were not observed. As depicted graphically
in Fig. 3, transplantation was associated with a decline in
HDL-C levels in nearly all COPD subjects, and increased
prednisone use following transplantation reduced the
magnitude of the decline.
Several observations could support a link between COPD
pathophysiology and abnormal lipid metabolism. The
Fig. 3 Effect of change in prednisone exposure on change in
HDL-C with transplant in COPD cohort.
Table 3 Effect of calcineurin inhibitor selection on lipid
changes with transplantation in COPD.
Change with transplant
(mg/dL)a
Pa
Total cholesterol (mg/dL)
Cyclosporine 26 (9e63) 0.03
Tacrolimus 25 (57 to 25)
Triglycerides (mg/dL)
Cyclosporine 86 (22e125) 0.97
Tacrolimus 67 (35e145)
LDL-C (mg/dL)
Cyclosporine 23 (11e69) 0.014
Tacrolimus 17 (55 to 18)
HDL-C (mg/dL)
Cyclosporine 23 (12 to 43) 0.48
Tacrolimus 26 (12 to 36)
a Data are expressed as median (IQR).
b P values were obtained through Wilcoxon rank-sum tests
comparing cyclosporine (n Z 15) and tacrolimus (n Z 46)
groups.
1966 R.M. Reed et al.inflammatory cell most implicated in both processes is the
macrophage. Macrophages in COPD are hyperactive,
present in concentrations 5e10 fold over normal values,
and the degree of elevation correlates to COPD disease
severity.20 Macrophages produce phospholipid transfer
protein (PLTP)21 which is predominately found in the lungs.
PLTP exhibits enhanced expression with a hypoxic stimulus,
particularly in emphysematous lungs,22 and some evidence
suggests a direct correlation with HDL-C.23 PLTP may be one
of the mechanisms explaining the observation that inter-
mittent hypoxia can raise HDL-C both in murine models24
and in human subjects with coronary disease.25 Further-
more, PLTP may play a key role in extracting phospholipids
from HDL for normal surfactant production.26e28 AirwayTable 4 Correlates of change in HDL-C in COPD cohort.
Univariate Analysis Pearson’s
Coefficient
P value
Change in Prednisone Dose 0.82 0.02
Azathioprine 8.6 0.06
Female Gender 11 0.11
Age 0.67 0.17
Tacrolimus vs. Cyclosporine 9.5 0.23
ΔBMI 0.61 0.24
Diabetes Mellitus Post-
Transplant
4.7 0.55
Mycophenolate 3.12 0.67
Multivariable Analysisa
Change in Prednisone Dose 0.83 0.013
Female Gender 11 0.1
ΔBMI, change in body mass index; ΔFVC%, change in percent
predicted forced vital capacity; ΔFEV1%, change in percent
predicted forced expiratory volume in 1 s.
a Variables with P  0.4 in univariate analysis were evaluated
for inclusion in multivariate model by comparison of AIC using
stepwise regression with threshold for inclusion of P < 0.2.surfactant is highly enriched with phospholipids, and
dysfunctional surfactant has been implicated in the path-
ogenesis of COPD.29 It is unlikely, however, that PLTP is the
only factor involved in lipid abnormalities in COPD.
Surfactant phospholipid content and surfactant release are
also influenced by HDL and vitamin D. Vitamin D-binding
protein gene polymorphisms have been associated with
COPD susceptibility30,31 and may in turn exert regulatory
effects on HDL-C levels.32
There is an inverse relationship between serum levels of
HDL-C and risk for cardiovascular disease.33 HDL particles
are widely believed to be atheroprotective because of their
capacity to drive reverse cholesterol transport, normalize
endothelial dysfunction, and inhibit oxidation, inflamma-
tion, insulin resistance, and thrombosis.34 Hence, the
decline in HDL-C with lung transplantation could indicate
an increase in cardiovascular risk. Studies in other pop-
ulations have consistently demonstrated an increased risk
for cardiovascular events on the order of 2e3% per 1 mg/dL
reduction in HDL-C.35 While the magnitude of the risk
attributable to the lipid changes observed in patients
undergoing lung transplantation remains unclear, the
median decline in HDL-C of 25 mg/dL is substantial, and
cardiovascular mortality remains a major contributor to
death following lung transplantation, accounting for nearly
11% of deaths within the first 30 days of transplantation.6
Study limitations
This study is retrospective, represents a highly selected
group of subjects with very severe COPD, and does not
allow determination of mechanism. It also does not directly
evaluate cardiovascular morbidity and mortality.Conclusions
In patients with COPD, lung transplantation results in
reduced HDL cholesterol and increased LDL-C/HDL-C ratios.
The decline in HDL-C values is not explained by changes in
BMI, or new onset diabetes mellitus, and is partially
attenuated by increased prednisone exposure post-
Impact of lung transplantation on serum lipids in COPD 1967transplant. Similar changes do not occur in subjects
undergoing lung transplantation for diagnoses other than
COPD.
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